Last quarter (Q ), Anthera Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Anthera Pharmaceuticals's net income was $-6.02M. See Anthera Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 17	Dec 16	Dec 15	Dec 14	Dec 13
Total Revenue	-	-	$ 145.00K	$ 3.19M	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	$ 145.00K	$ 3.19M	$ 0.00	$ 0.00
Operating Expense	$ -14.86M	$ 36.43M	$ -57.32M	$ 38.43M	$ 28.46M	$ 28.25M
Operating Income	$ -36.80M	$ -36.43M	$ -57.18M	$ -35.24M	$ -28.46M	$ -28.25M
Net Non Operating Interest Income Expense	$ 4.93M	-	$ 1.74M	-	$ -1.05M	$ -2.60M
Other Income Expense	$ 11.04M	$ -9.56M	$ -1.65M	$ 23.00K	$ -96.00K	$ -15.00K
Pretax Income	$ -21.75M	$ -26.87M	$ -55.52M	$ -35.22M	$ -29.60M	$ -30.86M
Tax Provision	$ -28.63M	$ -28.93M	$ -8.94M	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	$ 1.74M	-	-	-
Net Income Common Stockholders	$ -23.29M	$ -29.38M	$ -66.44M	$ -35.22M	$ -29.60M	$ -30.86M
Basic EPS	$ -0.55	-	-	$ -7.92	$ -10.88	$ -13.52
Diluted EPS	$ -1.25	$ -2.86	$ -12.87	$ -7.92	$ -10.88	$ -13.52
Basic Average Shares	$ 53.53M	$ 10.28M	$ 157.00	$ 4.45M	$ 2.72M	$ 2.28M
Diluted Average Shares	$ 43.25M	$ 10.28M	-	$ 4.45M	$ 2.72M	$ 2.28M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -14.86M	$ 36.43M	$ -57.32M	$ 38.43M	$ 28.46M	$ 28.25M
Net Income From Continuing And Discontinued Operation	$ -25.00M	$ -26.87M	$ -55.52M	$ -35.22M	$ -29.60M	$ -30.86M
Normalized Income	$ -12.98M	-	-	$ -35.22M	$ -29.51M	$ -30.85M
Interest Expense	-	-	-	-	$ 1.05M	$ 2.60M
EBIT	$ -30.72M	$ -26.87M	$ -55.52M	$ -35.24M	$ -28.55M	$ -28.26M
EBITDA	$ -30.33M	$ -26.59M	$ -55.26M	$ -34.96M	$ -28.21M	$ -27.91M

Currency in USD

Anthera Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing